|Dr. Sven Ante Lundberg||CEO, Pres, Principal Financial Officer & Exec. Director||986.82k||N/A||1963|
|Mr. Peter B. Silverman J.D.||Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal||614.88k||N/A||1978|
|Mr. Hui Liu||Chief Bus. Officer, Exec. VP & Head of Merus U.S.||611.31k||N/A||1967|
|Dr. Hennie Hoogenboom||Co-Founder and Scientific Advisor||N/A||N/A||N/A|
|Mr. Cornelis Adriaan de Kruif Ph.D.||CTO & Sr. VP||N/A||N/A||1964|
|Dr. Cecile A.W. Geuijen Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Jillian Connell||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Alexander Berthold Hendrik Bakker Ph.D.||Chief Devel. Officer & Sr. VP||N/A||N/A||1967|
|Dr. Andrew Joe M.D.||Chief Medical Officer||N/A||N/A||1966|
|Ms. Anne Van der Touw Noordzij||Company Sec.||N/A||N/A||N/A|
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Merus N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.